CIBC World Market’s Lexicon Pharmaceuticals LXRX Stock Holding History

CIBC World Market’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,980	Closed	-$18K	–	1363
2024 Q2	$18K	Buy	+10,980	New	+$19.7K	﹤0.01%	1255

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CIBC World Market's LXRX Position: Q3 2024 in Review

CIBC World Market sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2024, closing a stake of 10,980 shares — an estimated $18K sold.

CIBC World Market first reported a position in LXRX in Q2 2024 and held it in 1 quarter. The position peaked at $18K in Q2 2024. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2024.

CIBC World Market reported no remaining Lexicon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
CIBC World Market sold 10,980 Lexicon Pharmaceuticals shares in Q3 2024, an estimated $18K.
CIBC World Market first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 1 quarter.
CIBC World Market's Lexicon Pharmaceuticals position peaked at $18K in Q2 2024.
137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2024.

Based on CIBC World Market's 13F filing for Q3 2024, filed 12 Nov 2024.